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Clenbuterol is a sympathicomimetic agent with a
predominant effect on beta2-adrenergic receptors
[6]. In addition to its bronchospasmolytic effect it
inhibits uterine contractions and has been re-
commended for treatment of premature labor [6].
The results of pharmacokinetic studies in non-
pregnant animals [4, 7] and in nonpregnant human
individuals [8] indicate rapid absorption of an oral
dose of Clenbuterol by the gastro-intestinal tract,
resulting in relatively high plasma levels of the un-
changed compound. Elimination of orally ad-
ministered isotope-labelled Clenbuterol was shown
to follow a biphasic curve with a half-life of 30—
35 hours in the second, slow phase [8].
If these pharmacologic properties would also be
valid in pregnant women with uterine contrac-
tions, oral administration of Clenbuterol would
appear to be an attractive approach to the treat-
ment of premature labor. Therefore, the present
study was designed to measure the effects of single
oral doses of Clenbuterol on uterine activity äs
well äs on variables of maternal and fetal cardio-
vascular function.
The study was performed in term pregnant women
with oxytocin-induced labor in order to obtain
standardized uterine activity and to allow continu-
ous measurement of in trauterine pressure and fetal
heart rate.
l Patients and methods
Informed consent for this study was obtained
from ten nulliparous and fifteen parous women
who received obstetric care at the AZR-Dijkzigt
Clinic and had opted for elective induction of
labor. The general and obstetric history of all
women was negative with regard to major diseases
and complications of pregnancy, and the course of
the present pregnancy was uncomplicated with
normal fetal growth äs confirmed by ultrasonic
measurement of the fetal biparietal diameter. All
women presented between 39 and 42 weeks of
amenorrhea with a single fetus in the cephalic
Position and a ripe cervix according to the BURN-
HiLL-score [1].
l. l Induction of labor and monitoring
Labor was induced by means of low amniotomy
followed by intravenous infusion of incremental
doses of oxytocin. No other drugs were used
except for the occasional administration of pethi-
dine-HCl for pain relief. An open-tip catheter filled
with sterile destilled water was introduced trans-
cervically into the amniotic cavity for continuous
measurement of uterine activity and a Spiral elec-
trode (Corometrics B-2462) was attached to the
fetal scalp for continuous recording of the fetal
EKG and cardiotachogram. A maternal tachogram
was derived from the maternal EKG and maternal
blood pressure was measured between uterine con-
tractions at 10 minute intervals with an automatic
ultrasound device (Arteriosonde, Röche). All
Signals were written on a multichannel polygraph
and recorded on magnetic tape.
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l .2 Experimental protocol
Starting with 1.8 mU per minute the dose of oxy-
tocin was increased stepwise until stable uterine
activity of three contractions per 10 minutes with
an intensity of approximately 50 mm of Hg at a
constant oxytocin infusion rate was obtained
during a control period of at least 30 minutes.
Then a vaginal examination was done to assess the
degree of cervical dilatation and engagement of the
fetal head and Clenbuterol* was given in a single
oral dose of 40, 80 or 160 & The effects on
uterine activity and on maternal and fetal cardio-
vascular variables were measured during an experi-
mental period of at least 130 minutes following
the administration of Clenbuterol, except in cases
in which delivery occurred within that period of
, time. The oxytocin infusion rate was kept con-
stant during the experimental period. The data
was analyzed by means of an appropriately pro-
grammed Computer (FDP-11/70). Uterine activity
was calculated by multiplying the maximum
height (mm Hg) of the pressure curve äs measured
from a level of 20 mm of Hg times the interval
(min) between the two points of intersection of
the 20 mm Hg level with the pressure curve [5].
The advantage of using a 20 mm Hg level äs a
reference line is that it allows sharp definition of
the "onset" and the "end" of a uterine contrac-
tion. The products of intrauterine pressure and
time thus calculated for.qach contraction during
a period of time of 10 minutes were added and
expressed äs uterine activity units (ÜAUs). Women
who showed a decrease in uterine activity units
of 10% or more during two consecutive periods
of 10 minutes in the experimental period äs com-
pared with the mean uterine activity in the control
period were labelled "responders".
Appropriate non-parametric tests were applied
where necessary for statistical analysis and p < 0.05
was chosen äs the level of significance.
2 Results
Relevant data of the women involved in the study
is summarized in Table L There were no differerices
at the end of the control period between patients
receiving 40, 80 or 160 ^g of Clenbuterol with
regard to age, weight, duration of pregnancy,
cervical dilatation and engagement of the fetal
head, and uterine activity.
2.1 Effect on uterine activity
In 10 out of the 25 women uterine activity de-
creased following an oral dose of Clenbuterol
(Tab. I). In the remaining 15 women uterine
;·:
(ft
Tab. I. Relevant data of women receiving an oral dose of Clenbuterol during oxytocin-induced labor.
Dose Number
of of patients
Clen-
blf- Nulli- Par-
ro1
 par- ous
Responders
Non-
responders
Responders
Non-
responders
Responders
Non-
responders
(Mg)
40
40
80
80
160
160
ous
4
1
1
3
1
0
Age Weight
(yrs)1
0
4
2
3
2
4
26.5
25.8
27.3
27.5
25.3
24.5
(23-31)
(22-30)
(22-30)
(20-35)
(23-27)
(21-27)
(kg)1
86
81
86
69
78
79
(75-118)
(76-87)
(69-97)
(65-78)
(65-103)
(60-108)
Amenorrhea1
(weeks)
40
39
39
40
40
40
(39-42)
(38-40)
(39-40)
(39-41)
(39-41)
(39-42)
Cervical
dilatation [
at end of
control
period
(cm)
2 (1-3)
3 (2-4)
2 (2-3)
2 (2-3)
3 (2-4)
3 (2-4)
Uterine
activity in
control
period
(UAU)2
111.7 ± 8.6
89.8 ±18.6
96.8 ± 18.5
80.0 ± 19.7
89.3 ± 10.5
94.0 ± 26.8
1
 Mean (ränge) 2 Mean ± S.D.
* Gift from Boehringer-Ingelheim, Haarlem, the Nether-
lands.
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activity remained equal or increased during the
experimental period. A decrease in uterine activity
was observed in six out of ten nulliparous women,
and in four out of 15 parous patients; the differ-
ence is not significant (FISHER test). The fall in
uterine activity following 40 g of Clenbuterol was
significantly less than that following an 80 or a
160 g dose (Fig. 1), but no difference was appar-
ent between the effect of an 80 mg and a 160 mg
dose.
160 Mg
Fig. 1. Uterine activity (UAUs) expressed äs a percentage
of the control value in 10 women responding to an oral
dose of 40,80 or 160 Mg of Clenbuterol.
The decrease in uterine activity äs measured in
UAUs appeared to be due to a simultaneous de-
crease in frequency and in intensity of the con-
tractions. The labor-inhibiting effect of Clenbute-
rol became apparent in all responders 30—40 min-
utes after oral administration, the maximum fall in
uterine activity occurred after 60—80 minutes. In
the 40 Mg group uterine activity in 2 of the 4 re-
sponders returned to the control level within two
hours. In the remaining responders uterine activity
was still significantly decreased two hours after
administration of Clenbuterol.
The mean duration of the first stage of labor fol-
lowing oral administration of Clenbuterol was 501
(ränge 140—1800) minutes in nulliparous re-
sponders, which is significantly longer than the
130 (ränge 110-400) minutes observed in nulli-
parous non-responders. In the parous responders
the first stage of labor following Clenbuterol had
a mean duration of 280 (ränge 155—495) minutes,
which is significantly longer than that in the
parous non-responders (mean 97 min, ränge 43—
270 min). Three hours following an 80 % dose in
one responder and 160 ^g in two responders
uterine activity was still 50% or less ofthat in the
control period. In these cases, oral administration
of 40 mg of propranolol resulted in the return of
adequate uterine contractions.
2.2 Maternal and fetal cardiovascular effects
In the groups receiving 40 or 80 % of Clenbuterol
no significant trend in maternal blood pressure or
heart rate was observed during the experimental
period.
No differences were apparent with regard to these
variables between responders and non-responders.
In the three women who responded to 160 % of
Clenbuterol a marked increase in heart rate was
observed, which started between 40 and 60 min-
utes after receiving Clenbuterol. In one patient the
heart rate increased to 145 beats per minute with
serious palpitations, whereas systolic and diastolic
blood pressure remained stable. This responder
showed the greatest fall in uterine activity ob-
served in this group. The rise in heart rate was
absent in the non-responders in this group (Fig. 2).
Systolic blood pressure showed a slight increase
and diastolic blood pressure feil at about 60 min-
utes following an oral dose of 160 ^ g of Clenbute-
rol in responders, to an average of 80% of its base-
line value.
Systolic
BP
-20-
MHR
20 60 80 100 120 110 min.
Fig. 2. Mean changes in maternal blood pressure (BP) and
heart rate (MHR), expressed äs percentages of control
values, in women receiving an oral dose of 160 /ig of
Clenbuterol. ·—« responders (n = 3); ·—o non-re-
sponders (n = 4).
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Fetal heart rate patterns remained unchanged in
all cases. All infants were born alive and in good
condition.
3 Discussion
The effect of an oral dose of Clenbuterol on
uterine activity in parturient women in the begin-
ing of the first stage of labor appears to be vari-
able: in 60% of our patients no effect at all was
seen, whereas uterine activity was clearly inhibited
in the remaining 40%.
In the responders the decrease in uterine activity
was less marked with a 40 μg dose than with 80 or
160 μg of Clenbuterol. Since no difference was
apparent between the degree of myometrial Inhibi-
tion obtained with 80 //g and that following
160 Mg, 80 Mg of Clenbuterol appears to be an
optimal oral dose.
All responders show a similar pattern of Inhibition
of myometrial activity: labor activity begins to
decrease 30—40 minutes after oral administration
of Clenbuterol, and a maximum fall in uterine
activity is observed after 60—80 minutes, followed
by a gradual increase in frequency and intensity
of uterine contractions. The effect of Clenbuterol
appears to be long-lasting: uterine activity was still
significantly reduced two hours after oral adminis-
tration in all responders except in two patients
who received a 40 Mg dose.
Our finding that more than half the number of
women studied did not respond at all might be
attributed to absent or inadequate intestinal ab-
sorption of the agent due to delayed gastric
emptying in these cases. Clenbuterol is absorbed
by the intestinal tract and it is known that gastric
emptying often stops completely during labor [2].
Because a plasma assay of Clenbuterol was not
available we were unable to adduce direct evidence
to support or refute this hypothesis.
The absence of significant differences in cervical
dilatation, engagement of .the presenting part, and
baseline uterine activity at the time of administra-
tion of Clenbuterol between responders and non-
responders makes it unlikely that the variability of
the response to Clenbuterol could be due to differ-
ences in the degree of labor.
Effects of Clenbuterol on maternal blood pressure
and heart rate were apparent in all responders who
received 160 Mg of Clenbuterol, but were absent in
the non-responders, which lends indirect support
to the hypothesis of poor absorption in these
cases. Maternal tachycardia was observed to Start
earlier than the fall in diastolic blood pressure, and
it was still present when diastolic blood pressure
had returned to its control value. This suggests a
direct positive chronotropic effect of Clenbuterol
on the maternal heart, but the limited number of
observations precludes firm conclusions in this
respect.
Although Clenbuterol has been shown to be trans-
ferred across the placenta in animal experiments
[4] we observed no effect on fetal heart rate, even
not in women who responded to an oral dose of
160 Mg.
In conclusion, an oral dose of 80 Mg of Clenbuterol
appears to inhibit uterine activity effectively and
with virtually no side effects during a period of
time of more than two hours, provided that it is
absorbed from the intestinal tract. However, in-
testinal absorption is known to be variable during
labor due to the delay in gastric emptying. For
this reason and also because of the relatively
delayed onset of action, oral administration of
Clenbuterol cannot be recommended for acute
treatment of premature labor. However, it could
be an attractive approach to maintenance of
therapy once uterine contractions have been
effectively inhibited by means of an intravenously
administered sympathicomimetic agent, or to pre-
vention of threatened premature labor.
Summaiy
The effects of a single oral dose of the beta-sympathico-
mimetic agent Clenbuterol on uterine activity and mater-
nal and fetal cardiovascular variables were experimentally
investigated in 25 women in the first stage of oxytocin-
induced labor. Intra-amniotic pressure, and fetal and
maternal heart rate were continuously recorded, and
maternal blood pressure was measured with an ultrasound
device at 10 minute intervals. Myometrial contractility
was expressed in uterine activity units (UAUs). After
stable uterine activity of between 80 and 110 UAUs was
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obtained, an oral dose of 40, 80, or 160 Mg of Cienbute-
rol was given. In 10 women uterine contractionsdecreased
following a single oral dose of Cienbuterol (responders),
whereas in the remaining 15 women no effect on myo-
metrial activity was observed (non-responders). In re-
sponders the fall in uterine activity following a 40 Mg
dose was significantly less than that following an 80 or
160 Mg dose, but the difference between 80 and 160 Mg
was not significant. In all responders the labor-inhibiting
effect of Cienbuterol became apparent 30-40 minutes
following oral administration, and the maximum decrease
in uterine activity occurred after 60-80 minutes. Except
in women who received 40 Mg, the effect lasted at least
2 hours in all responders. An increase in maternal heart
rate together with a rise in systolic blood pressure and a
slight fall of the diastolic pressure were observed in re-
sponders who received 160 Mg of Cienbuterol but were
absent in the other responders. Effects on fetal heart rate
were never demonstrated. The absence of a response even
to a high dose of Cienbuterol in 15 out of 25 women in
early labor might be attributed to absent or inadequate
intestinal absorption of the agent due to delayed gastric
emptying which is known to occur during labor. On the
basis of these findings we conclude that oral administra-
tion of Cienbuterol cannot be recommended for acute
treatment of premature labor but could be an attractive
approach to maintenance of therapy once uterine con-
tractions have been effectively inhibited by means of an
intravenously administered sympathicomimetic agent, or
to prevention of threatened premature labor.
Keywords: Beta-sympathicomimetic drugs, clenbuterol, Inhibition of labor, uterine relaxation.
Zusammenfassung
Die Beeinflussung der oxytocininduzierten Uteruskon-
traktionen durch orale Clenbuterolgabe
In unserer Untersuchung sollte der Einfluß einer Einzel-
dosis des Betasympathomimetikums Cienbuterol auf die
Uterustätigkeit sowie die mütterlichen und fetalen cardio-
vaskulären Parameter bei oxytocin-induzierten Wehen ge-
prüft werden. Das Untersuchungskollektiv bestand aus
25 Frauen in der Eröffnungsphase. Der intraamniale
Ehruck sowie die maternale und fetale Herzfrequenz wur-
den kontinuierlich aufgezeichnet; die Messung des mütter-
lichen Blutdrucks erfolgte über Ultraschallableitung in
Abständen von 10 Minuten. Maß für die Kontraktibilität
des Myometriums waren ,uterine Aktivitätseinheiten
(ÜAU's)'. Wenn die Uterustätigkeit eine Stärke von
80-110 UAU's erreicht hatte, verabreichten wir oral 40,
80 oder 160 Mg Clenbuterol. Bei 10 Frauen erfolgte dar-
aufhin ein Abfall der Uterusaktivität, während bei den
restlichen 15 Frauen kein Effekt zu beobachten war. Die
Abnahme nach 40 Mg war signifikant geringer als nach
80 Mg und 160 Mg. Zwischen 80 Mg und 160 Mg ließ sich
aber kein statistisch signifikanter Unterschied nachwei-
sen. Der wehenhemmende Effekt setzte schon nach 30
bis 40 Minuten ein und erreichte sein Maximum nach 60
bis 80 Minuten. Mit Ausnahme der Frauen, die 40 Mg er-
halten hatten, hielten die Effekte über 2 Stunden an. Ein
Anstieg der mütterlichen Herzfrequenz zusammen mit
einem erhöhten systolischen Druck und einem leicht er-
niedrigten diastolischen Wert fand sich nur bei den
Frauen, die die höchste Dosierung von 160 Mg Clenbuterol
erhalten hatten. Die fetale Herzfrequenz wurde überhaupt
nicht beeinflußt. Daß 15 Frauen selbst auf hohe Dosen
gar nicht ansprachen, führen wir auf eine fehlende oder
inadäquate intestinale Resorption zurück; es ist bekannt
daß während der Geburt die Magenentleerung verzögert
ist. Aus unseren Ergebnissen folgern wir, daß die orale
Gabe von Clenbuterol als Therapie bei der Frühgeburt
nicht empfohlen werden kann. Sinnvoll erscheint es aber,
Clenbuterol als Erhaltungsdosis zu verabreichen, wenn die
Uteruskontraktionen durch i. v. verabreichte Sympatho-
mimetika effektiv gehemmt werden konnten oder in der
Prävention bei drohender Frühgeburt einzusetzen.
Schlüsselwörter: Betasympathomimetika, Clenbuterol, Relaxierung des Uterus, Wehenhemmung.
Resume
Effets de Fadministration orale de Clenbuterol sur Pactiv-
ite uterine induite par Foxytocine
Les effets d'une prise orale unique de Clenbuterol,
medicament betamimetique sur Pactivit6 uterine et sur les
parametres cardio-vasculaires de la mere et du foetus, ont
ete explores chez 25 femmes au cours de la premiere
partie du travail declenche par Focytocine. La pression
intra-amniotique et le rythme cardiaque du foetus et de la
mere ont ete enregistres de fa$on con tinue; la pression
arterielle maternelle a ete mesuree toutes les 10 minutes
a l'aide d'un dispositif ultra-sonore. L'activite contractile
du myometre a ete exprimee en unites d'activite uterine
(UAU). Lorsque une activite uterine stable comprise entre
80 et 110 UAU est obtenue, une prise orale de 40, 80 ou
160 Mg de Clenbuterol est donnee. Chez 10 femmes les
contractions uterines ont diminue a la suite d'une prise
orale unique de Clenbuterol (repondeurs), tandis que chez
les 15 femmes restantes, aucun effet sur Pactivite
myometriale n'a ete note (non-repondeurs). Dans le
groupe des repondeurs, la chute de Pactivite uterine a la
suite d'une dose de 40 Mg est de fa^on significative
moindre que celle suivant une dose de 80 ou de 160 Mg,
mais la difference entre 80 et 160 Mg n'est pas signi-
ficative. Chez toutes les repondeurs Peffet d'inhibition sur
le travail du Clenbuterol se manifeste 30 a 40 minutes
apres la prise orale, et la diminution maximale de Pactivite
uterine se produit au bout de 60 a 80 minutes. A Pexcept-
ion des femmes ayant re$u 40 Mg, Peffet s'acheve au bout
d'au moins 2 heures dans le groupe repondeurs. Une
augmentation du rythme cardiaque maternel associee a
une elevation de la pression systolique et a une legere
diminution de la diastolique ont ete observees chez les
femmes repondeurs ayant irequ 160 Mg de Clenbuterol,
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modifications non retrouvees chez les autres femmes du
groupe. Π n'a jamais ete demontre d'effets sur le rythme
cardiaque foetal. L'absence de reponse meme a une dose
elevee de Clenbuterol chez 15 des 25 femmes en debut de
travail peut 6tre attribuee a une absorption intestinale
absente ou inapropriee de la drogue en rappoit avec le
retard de Pevacuation gastrique que Γόη observe pendant
le travail. Sur la base de ces donnees les auteurs conclu-
ent que la prise orale de Clenbuterol ne peut etre
recommandee comme traitement d'urgence du travail
premature mais peut etre urfe voie interessante pour
poursuivre le traitement une fois que les contractions
uterines ont ete efficacement inhibees au moyen d'une
perfusion intra-veineuse de betamimetiques ou pour la
prevention de la menace d'accouchement premature.
Mots-cles: Clenbuterol, Inhibition du travail, medicaments betamimetiques, relaxation uterine.
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